Asset Management One Co. Ltd. Has $45.18 Million Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• Asset Management One Co. Ltd. increased its holdings in Bristol Myers Squibb by 4.3% to 976,025 shares, valued at $45.18 million, during Q2, as per its recent SEC filing.
• Bristol Myers Squibb reported $1.46 EPS for Q2, exceeding analysts' estimates of $1.07, with revenue reaching $12.27 billion against expectations of $11.32 billion.
• The company announced a quarterly dividend of $0.62 per share, representing a 5.7% dividend yield, and has set its FY 2025 EPS guidance at $6.350-6.650.

Asset Management One Co. Ltd. boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 4.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 976,025 shares of the biopharmaceutical company's stock after buying an additional 39,965 shares during the period. Asset Management One Co. Ltd.'s holdings in Bristol Myers Squibb were worth $45,180,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Bristol Myers Squibb during the first quarter worth $31,000. Trifecta Capital Advisors LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth $25,000. Accent Capital Management LLC acquired a new stake in Bristol Myers Squibb during the first quarter worth $33,000. CBIZ Investment Advisory Services LLC boosted its stake in Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 231 shares in the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new stake in Bristol Myers Squibb during the first quarter worth $36,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $43.84 on Friday. The stock has a 50-day simple moving average of $45.75 and a 200 day simple moving average of $47.14. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The stock has a market capitalization of $89.24 billion, a price-to-earnings ratio of 17.68, a P/E/G ratio of 2.29 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm's revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.7%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb's payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent research reports. Citigroup reiterated a "neutral" rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Weiss Ratings reissued a "hold (c-)" rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Daiwa America cut Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Daiwa Capital Markets cut Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective for the company. in a report on Tuesday, August 5th. Finally, Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and an average target price of $57.23.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company's stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by company insiders.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.